Colonoscopic evaluation in ulcerative colitis

Gastroenterology Report

Volumn 2, Issue 3, 2014, Pages 161-168

  Paine, Elizabeth R ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Colonoscopic evaluation; Disease activity; Mucosal healing; Ulcerative colitis

Indexed keywords

EID: 84962770927     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gou028     Document Type: Review

References (62)

1. Ordas I, Eckmann L, Talamini M et al. Ulcerative colitis. Lancet 2012;380:1606-19.
2. Langan RC, Gotsch PB, Krafczyk MA et al. Ulcerative colitis: diagnosis and treatment. Am Fam Physician 2007;76:1323-30.
3. Leighton JA, Shen B, Baron TH et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006;63:558-65.
4. Carter MJ, Lobo AJ, Travis SP et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53 (Suppl 5), V1-16.
5. Magro F, Rodrigues A, Vieira AI et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis 2012;18:573-83.
6. Regueiro M, Loftus EV Jr, Steinhart AH et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis 2006;12: 972-78.
7. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 (Suppl A), 5A-36A.
8. Regueiro MD. Diagnosis and treatment of ulcerative proctitis. J Clin Gastroenterol 2004;38:733-40.
9. Gionchetti P, Rizzello F, Morselli C et al. Review article: problematic proctitis and distal colitis. Aliment Pharmacol Ther 2004;20 (Suppl 4), 93-96.
10. Dignass A, Lindsay JO, Sturm A et al. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6: 991-1030.
11. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull 1999;46:400-15.
12. Miner P and Kirsner J. Clinical features, course, laboratory findings, and complications in ulcerative colitis. In: Kirsner J (ed.). Inflammatory bowel disease. 5th ed. Philadelphia: WB Saunders, 2000, 299-304.
13. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53.
14. Rogler G. Medical management of ulcerative colitis. Dig Dis 2009; 27:542-49.
15. Navaneethan U, Jegadeesan R, Gutierrez NG et al. Backwash ileitis and the risk of colon neoplasia in ulcerative colitis patients undergoing restorative proctocolectomy. Dig Dis Sci 2013;58: 2019-27.
16. Yamamoto T, Maruyama Y, Umegae S et al. Mucosal inflammation in the terminal ileum of ulcerative colitis patients: endoscopic findings and cytokine profiles. Dig Liver Dis 2008;40: 253-59.
17. Gustavsson S, Weiland LH and Kelly KA. Relationship of backwash ileitis to ileal pouchitis after ileal pouch-anal anastomosis. Dis Colon Rectum 1987;30:25-28.
18. Heuschen UA, Hinz U, Allemeyer EH et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001;120:841-47.
19. Yamaguchi N, Isomoto H, Shikuwa S et al. Proximal extension of backwash ileitis in ulcerative colitis-associated colon cancer. Med Sci Monit 2010;16:CS87-91.
20. Naves JE, Lorenzo-Zuniga V, Marin L et al. Long-term outcome of patients with distal ulcerative colitis and inflammation of the appendiceal orifice. J Gastrointestin Liver Dis 2011;20:355-58.
21. Rubin DT and Rothe JA. The peri-appendiceal red patch in ulcerative colitis: review of the University of Chicago experience. Dig Dis Sci 2010;55:3495-501.
22. Kroft SH, Stryker SJ and Rao MS. Appendiceal involvement as a skip lesion in ulcerative colitis. Mod Pathol 1994;7:912-14.
23. Matsumoto T, Nakamura S, Shimizu M et al. Significance of appendiceal involvement in patients with ulcerative colitis. Gastrointest Endosc 2002;55:180-85.
24. D'Haens G, Geboes K, Peeters M et al. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol 1997;92:1275-79.
25. D'Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
26. Schroeder KW, Tremaine WJ and Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-29.
27. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
28. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60: 780-87.
29. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology 2012;142:257-65;e1-3.
30. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146: 85-95.
31. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab maintains clinical response in patients with moderateto-severe ulcerative colitis. Gastroenterology 2014;146:96-109; e1.
32. Travis SP, Schnell D, Krzeski P et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535-42.
33. Baron J, Connell A and Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964;1:89.
34. Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507.
35. Thia KT, Loftus EV Jr, Pardi DS et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis 2011;17:1257-64.
36. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-86.
37. Sutherland LR, Martin F, Greer S et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-98.
38. Matts SF. The value of rectal biopsy in the diagnosis of ulcerative colitis. QJM 1961;30: 393-407.
39. Blackstone MO. Inflammatory bowl disease. In: Blackstone MO (ed). Endoscopic interpretation: normal and pathologic appearances of the gastrointestinal tract. New York: Raven Press, 1984, 464-94.
40. Samuel S, Bruining DH, Loftus EV Jr et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2013;11: 49-54;e1.
41. Travis SP, Schnell D, Krzeski P et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013;145:987-95.
42. Annese V, Daperno M, Rutter MD et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7:982-1018.
43. Neurath MF and Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619-35.
44. Fratila OC and Craciun C. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. J Gastrointestin Liver Dis 2010;19:147-53.
45. Korelitz BI. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis 2010;16: 1628-30.
46. Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
47. Rogler G, Vavricka S, Schoepfer A et al. Mucosal healing and deep remission: what does it mean? World J Gastroenterol 2013;19: 7552-60.
48. Seldenrijk CA, Morson BC, Meuwissen SG et al. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut 1991;32: 1514-20.
49. Truelove SC and Richards WC. Biopsy studies in ulcerative colitis. BMJ 1956;1:1315-8.
50. Gomes P, du Boulay C, Smith CL et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92-95.
51. Riley SA, Mani V, Goodman MJ et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-78.
52. Froslie KF, Jahnsen J, Moum BA et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22.
53. Wright R and Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966;11:847-57.
54. Meucci G, Fasoli R, Saibeni S et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2012;18:1006-10.
55. Rutter MD, Saunders BP, Wilkinson KH et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004;53:1813-16.
56. Lichtenstein GR, Ramsey D and Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs 2.4 g/day in endoscopic mucosal healing: ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011;33:672-78.
57. Feagan BG and Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000543.
58. Jiang XL and Cui HF. Different therapy for different types of ulcerative colitis in China. World J Gastroenterol 2004;10:1513-20.
59. Truelove SC and Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. BMJ 1954;2:375-78.
60. Ardizzone S, Cassinotti A, Duca P et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9: 483-89;e3.
61. Lopez-Palacios N, Mendoza JL, Taxonera C et al. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. Eur J Intern Med 2011;22: 621-25.
62. Paoluzi OA, Pica R, Marcheggiano A et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002;16:1751-59.